Axsome Therapeutics Analysts Increase Their Forecasts Following Q2 Results

기사 요약

Axsome Therapeutics (NASDAQ:AXSM) reported Q2 losses of 99 cents per share and sales of $218.4 million, missing analyst estimates. Analysts have mixed price targets for the stock.